{"id":499658,"date":"2021-05-28T07:33:12","date_gmt":"2021-05-28T11:33:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/"},"modified":"2021-05-28T07:33:12","modified_gmt":"2021-05-28T11:33:12","slug":"verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/","title":{"rendered":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\u2013 Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 \u2013<\/p>\n<p align=\"left\">WEST CHESTER, Pa., May  28, 2021  (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to September 23, 2021.<\/p>\n<p>The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the Company\u2019s human factors study. On May 26, 2021, the FDA informed Verrica that the information submitted has been designated a major amendment, which allows FDA to take an additional three months to review the submitted information.<\/p>\n<p>\u201cWe remain confident in VP-102 as a potential treatment option for patients with molluscum,\u201d said Ted White, Verrica\u2019s President and Chief Executive Officer. \u201cImportantly, the FDA has recently completed one of the two pre-approval inspections required for approval. We look forward to our continued productive discussions with the FDA as it completes its review of our VP-102 NDA.\u201d<\/p>\n<p>\n        <strong>About VP-102<\/strong>\n      <\/p>\n<p>Verrica\u02bcs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w\/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. VP-102 is currently under U.S. Food and Drug Administration (FDA) review, with a PDUFA goal date of September 23, 2021, and could potentially be the first product approved by the FDA to treat molluscum contagiosum \u2015 a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH\u2122. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.<\/p>\n<p>\n        <strong>About Molluscum Contagiosum (Molluscum)<\/strong>\n      <\/p>\n<p>Molluscum is a highly contagious viral skin disease that affects approximately six million people \u2014 primarily children \u2014 in the United States. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites (objects that carry the disease like toys, towels or wet surfaces) and can spread to other parts of the body or to other people, including siblings. The lesions can be found on most areas of the body and may carry substantial social stigma. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.<\/p>\n<p>\n        <strong>About Verrica Pharmaceuticals Inc.<\/strong>\n      <\/p>\n<p>Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica\u2019s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cwill,\u201d and similar expressions, and are based on Verrica\u2019s current beliefs and expectations. These forward-looking statements include expectations regarding the Company\u2019s expectations with regard to the PDUFA date and potential approval of the NDA for\u00a0VP-102\u00a0and the potential benefits of\u00a0VP-102\u00a0for the treatment of molluscum, if approved. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica\u2019s reliance on third parties over which it may not always have full control, uncertainties related to the\u00a0COVID-19\u00a0pandemic and other risks and uncertainties that are described in Verrica\u2019s Annual Report on Form\u00a010-K\u00a0for the year ended\u00a0December 31, 2020 and other filings Verrica makes with the\u00a0U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>FOR MORE INFORMATION, PLEASE CONTACT:<\/strong>\n      <\/p>\n<p>Investors:<\/p>\n<p>\n        <strong>A. Brian Davis<\/strong><br \/>\n        <br \/>Chief Financial Officer<br \/>484.453.3300 ext. 103<br \/>info@verrica.com<\/p>\n<p>\n        <strong>William Windham<\/strong><br \/>\n        <br \/>Solebury Trout<br \/>646.378.2946<br \/>wwindham@soleburytrout.com<\/p>\n<p>Media:<\/p>\n<p>\n        <strong>Zara Lockshin<\/strong><br \/>\n        <br \/>Solebury Trout<br \/>646.378.2960<br \/>zlockshin@soleburytrout.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ec124c74-452b-44be-9a6d-506221c3bc3e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 \u2013 WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to September 23, 2021. The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499658","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 \u2013 WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to September 23, 2021. The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and &hellip; Continue reading &quot;Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-28T11:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum\",\"datePublished\":\"2021-05-28T11:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/\"},\"wordCount\":863,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/\",\"name\":\"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\",\"datePublished\":\"2021-05-28T11:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/","og_locale":"en_US","og_type":"article","og_title":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk","og_description":"\u2013 Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 \u2013 WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to September 23, 2021. The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and &hellip; Continue reading \"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-28T11:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum","datePublished":"2021-05-28T11:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/"},"wordCount":863,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/","name":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=","datePublished":"2021-05-28T11:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkyNiM0MjA2OTUyIzIxMjA3NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499658"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499658\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}